contract_awardAwarded Thursday, May 21, 2026Analyzed

SAPIENT GOVERNMENT SERVICES, INC.: $10.8M Department of Health and Human Services Contract

Neutral

Summary

This $10.8M contract to private entity Sapient Government Services for HRSA's BHW90 BMISS operations and maintenance is a routine renewal. No publicly traded company is directly tied, and the impact on the healthcare IT sector is minimal.

See which stocks are affected

Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.

Already have an account? Log in

Key Takeaways

  • 1.Contract is a routine $10.8M O&M renewal to a private company.
  • 2.No publicly traded company directly benefits; no tickers to trade.
  • 3.Healthcare IT sector sees minimal impact; focus on larger contracts or legislation.

Market Implications

This contract has no direct market implications for publicly traded companies. Investors should not adjust positions based on this award. The broader healthcare IT sector may see tailwinds from related legislation, but this specific contract is too small and opaque to drive stock moves.

Full Analysis

The Department of Health and Human Services, through the Health Resources and Services Administration, awarded a $10.8M BPA Call to Sapient Government Services, Inc. for FY26 BMISS Operations and Maintenance. BMISS likely refers to a health workforce data system. Sapient Government Services is a private entity, not a publicly traded company or recognized subsidiary of one. Therefore, no direct stock impact can be attributed. Because the recipient is private, no public company directly benefits from this award. The contract is a routine operations and maintenance renewal, not a new competitive win that would shift market share. The healthcare IT sector may see indirect benefits from sustained federal investment in health data systems, but this specific contract is too small to move any public company. Several related healthcare bills are in play, including HR6280 (Access to Genetic Counselor Services Act), HR7961 (H-1Bs for Physicians), HR8875 (Improving Home Dialysis Act), and HR8324 (Great American Healthcare Plan). These bills signal broader legislative support for healthcare workforce and technology, but none directly authorize this contract. The contract appears to be a standard renewal under existing appropriations. No supply chain beneficiaries can be reliably identified without knowing Sapient's subcontractors. Guessing would produce false positives. Historically, similar O&M contracts for federal health IT systems are routine and do not generate significant market movement for public companies unless they are prime contractors. Given the private recipient and routine nature, this contract has negligible impact on public equities. Investors should monitor larger HRSA IT contracts or legislative catalysts like the Great American Healthcare Plan for more actionable signals.

Related Presidential Actions

Executive orders & memoranda affecting the same sectors or companies

Exec OrderMay 29, 2026

Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries

This executive order directs the CDC and ACIP to review and potentially update the U.S. childhood vaccine schedule to align with recommendations from peer developed countries, which recommend fewer vaccines. It maintains insurance coverage for all currently available vaccines without cost sharing and emphasizes protecting religious liberty and parental authority.

Exec OrderApr 30, 2026

Promoting Efficiency, Accountability, and Performance in Federal Contracting

This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.

Exec OrderApr 18, 2026

Accelerating Medical Treatments for Serious Mental Illness

This executive order directs the FDA to prioritize review and facilitate 'Right to Try' access for psychedelic drugs, including ibogaine compounds, that have received Breakthrough Therapy designation for serious mental illnesses. It also allocates $50 million from HHS to support state programs advancing these treatments and mandates collaboration between HHS, FDA, VA, and the private sector to increase clinical trial participation and data sharing for these drugs. The Attorney General is further directed to expedite rescheduling reviews for approved Schedule I psychedelic substances.

Contract Details

Recipient

SAPIENT GOVERNMENT SERVICES, INC.

Award Amount

$10,798,683

Awarding Agency

Department of Health and Human Services

Sub-Agency

Health Resources and Services Administration

Contract Type

BPA CALL

Related Bills

HR6280HR7961HR8875HR8324